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 25 
Abstract 26 
Strategies to improve the immunogenicity of HIV-1 envelope (Env) antigens for more 27 
long lived, efficacious HIV-1 vaccine induced B-cell responses. HIV-1 Env gp140 28 
(native or un-cleaved molecules) or gp120 monomeric proteins elicit relatively poor 29 
B-cell responses which are short-lived. We hypothesized that Env engagement of the 30 
CD4 receptor on T-helper cells may result in anergic effects on T-cell recruitment and 31 
consequently a lack of strong robust and durable B-memory responses. To test this 32 
hypothesis we occluded the CD4 binding site (CD4bs) of gp140 by stable cross-33 
linking with a 3kD CD4 miniprotein mimetic serving to block ligation of gp140 on 34 
CD4+T-cells while preserving CD4 inducible (CDi) neutralizing and epitopes 35 
targeted by antibody dependent cellular cytotoxic (ADCC) effector responses. 36 
Importantly immunization of rhesus macaques consistently gave superior B-cell 37 
(p<0.001) response kinetics and superior ADCC (p<0.014) in a group receiving the 38 
CD4bs-occluded vaccine compared to those animals immunized with gp140. Of the 39 
cytokines examined, Ag-specific IL-4 T-helper ELISpots in the CD4bs-occluded 40 
group increased earlier (p=0.025) during the inductive phase. Importantly CD4bs-41 
occluded gp140 antigen not only induced superior B-cell and ADCC responses, the 42 
elevated B-cell responses proved to be remarkably durable lasting more than 60 43 
weeks post-immunization. 44 
 45 
Short title: Improved HIV vaccine B-cell responses using CD4bs occluded Env .  46 
 47 
48 
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Importance 49 
 50 
Attempts to develop HIV vaccines capable of inducing potent and durable B-cell 51 
responses have until now been unsuccessful. Antigen specific B-cell development and 52 
affinity maturation occurs in germinal centers in lymphoid follicles through a critical 53 
interaction between B-cells and T follicular helper cells. The HIV envelope binds the 54 
CD4 receptor on T-cells as soluble shed antigen or as antigen antibody complexes 55 
causing impairment in the activation of these specialized CD4 positive T-cells. We 56 
proposed that CD4-binding impairment may in part be responsible for the relatively 57 
poor B-cell responses to HIV envelope based vaccines. To test this hypothesis we 58 
blocked the CD4 binding site of the envelope antigen and compared it to currently 59 
used unblocked envelope protein. We found superior and durable B-cell responses in 60 
macaques vaccinated with an occluded CD4 binding site on the HIV envelope 61 
antigen, demonstrating a potentially important new direction in future design of new 62 
HIV vaccines. 63 
 64 
65 
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Introduction 66 
 67 
 Antibody (Ab) responses directed to the HIV-1 envelope have been correlated 68 
with protection from viral infection; however, the ability to induce the B-cell 69 
responses necessary to generate long-lived protective antibodies by vaccination has 70 
proven difficult. Impressive protection from in vivo challenge has been achieved 71 
repeatedly using passive transfer of broadly neutralizing monoclonal antibodies 72 
(bnAb) and these approaches are now being advanced by multiple groups to clinical 73 
proof-of-concept. Such bnAbs have been cloned from memory B-cells from HIV-1 74 
infected patients and sequence analysis has revealed substantial somatic 75 
hypermutation (SHM) from parental Ig germline (1) characteristic of high affinity 76 
maturation of antigen specific B-cells in germinal centers. CD4 positive T follicular 77 
helper cells (Tfh) play a fundamental role in Ab maturation by promoting Ig class 78 
switch recombination (CSR), SHM, B-cell selection and differentiation. A deeper 79 
understanding of these events may provide insights for improved HIV vaccine design. 80 
The close interaction of activated Ag specific CD4 T-cells and MHC II B-cells 81 
within germinal centers is critical for optimal development of anti-HIV Ab responses. 82 
Priming of naïve CD4+ T-cells is initiated by MHC class II positive dendritic cells in 83 
lymph nodes to differentiate into Tfh cells prior to their migration to the T-B cell 84 
interfaces of germinal centers (2–4) (GC). This promotes their encounter with B-cells 85 
that share the same Ag specificity that reinforces their lineage commitment and 86 
coalescence, mutual activation and formation of GC. Importantly it is the intensity of 87 
the Tfh signal which is dictated by the quality and longevity of B cell interactions 88 
with molecules expressed on the surface of Tfh cells (5). Signals from Tfh are critical 89 
for differentiation of GC B cells into memory B cells and long-lived plasma cells and 90 
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their maturation of Ig affinity by CSR and SHM (6). Those B cells with the strongest 91 
Tfh cell interactions are those that become memory B cells or leave the GCs and 92 
differentiate into long-lived plasma cells (7) . Importantly the cytokines, IL-21, IL-6 93 
and IL-4 play key roles in affinity maturation of Igs in B-cells. IL-21 which is central 94 
to Tfh development is augmented by IL-4 and together collaborate to promote Ig 95 
responses (8). Additionally, the tight regulatory program between Ag-specific B-cells 96 
in germinal centers is enhanced by the circulation and exchange of Tfh cells between 97 
B-cell rich germinal centers to ensure maximal diversification of CD4 T-cell help.  98 
Factors which interfere with Tfh activation and collaboration with B-cell 99 
development have a negative response on maturation of Ig responses and ultimately 100 
on their effector function. Of viruses which cause persistent infection, HIV is unique 101 
in that it utilizes the CD4 receptor with a specific high affinity CD4 binding site 102 
(CD4bs) on the envelope subunit gp120. Through the CD4bs the HIV Env gp120 103 
subunit can bind to the CD4 receptor in the absence of an intact infectious virion, 104 
either as a monomer or in its trimeric form (gp120 or gp140). Notably, HIV-1 and 2, 105 
and SIVs infect Tfh cells in GCs (9) and the Tfh population serves as the major T-cell 106 
compartment for HIV infection, replication, and production (10), ultimately 107 
contributing to the loss of CD4 T-cells and immune deficiency. However, very early 108 
in infection before numerical CD4 T-cell loss, HIV causes defects in CD4 T-cell and 109 
MHC class II APC cell function, defects which also affect B-cell responses infection. 110 
(11, 12) 111 
A growing number of studies have confirmed that gp120 alone or immune 112 
complexed with antibodies are likely to decrease CD4 T cell function (13). HIV-1 113 
replication is not only associated with virion-bound Env glycoprotein but with 114 
shedding of soluble gp120 or gp160 during replication in vivo (14,15). Soluble gp120 115 
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is found in plasma (16-18) and lymphoid tissues of HIV+ patients (19,20). This has 116 
been found to correlate with dysfunctional CD4+ T cell responses (18, 21, 22). A 117 
number of studies have demonstrated that gp120 binding to the CD4 receptor 118 
interferes with normal TCR-induced CD4+ T cell activation (19–21). The recent 119 
confirmation that gp120–immune complexes also engaged CD4 receptors and also 120 
prevent subsequent TCR-mediated activation of CD4+ T cells has raised concerns of 121 
over immunization with HIV envelope (13). 122 
Here we set out to examine the hypothesis that in a vaccine setting, CD4 binding 123 
HIV-1 envelope immunogens could potentially be detrimental to achieving optimal 124 
vaccine induced B-cell responses. To study this, we compared an HIV-1 gp140 125 
immunogen in which the binding to CD4 on the surface of T cell was abrogated by 126 
stable complexing of the antigen with a CD4 miniprotein mimetic that served to 127 
occlude the CDbs on the Env molecule. For this purpose we used scyllatoxin as a 128 
scaffold molecule from the scorpion, Leiurus quinquestriatus that mimics features of 129 
the CD4 reception which actually bind to the HIV Env glycoprotein (the b-hairpin of 130 
scyllatoxin can be superimposed on to positions 36 – 47 of the CDR2 loop of the CD4 131 
molecule). Subsequent transfer of the side chains of the amino acids of CD4 on to 132 
their equivalent positions of scyllatoxin resulted in a minipeptide which specifically 133 
binds to the HIV-1 Env glycoprotein CD4 binding site (CD4bs) with affinity for HIV-134 
1 equivalent to CD4 itself (22).  Notably, structural data demonstrates that the M64U1 135 
mimetic occludes the CD4 S-375 HIV-1 protein residue (23) which has been reported 136 
to enhance HIV-1 Env CD4 binding and virus replication in macaques (24). 137 
Importantly our design provided both CD4bs occlusion blocking high affinity binding 138 
Env residues such as S-375, while allowing and preservation of CD4i nAb epitopes 139 
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(with putative ADCC epitopes), both which we have demonstrated in previous 140 
structural and small animal studies (22, 25, 26). 141 
Since non-human primates have CD4 receptors on T-cells that are functionally 142 
and structurally very similar to human CD4, we studied this using 4 groups of 24 143 
macaques to determine if vaccine induced B-cell responses and effector responses 144 
such as ADCC could be improved by preventing CD4 engagement. Furthermore, to 145 
determine if the effect was determined at the level of CD4 T cells, we enumerated 146 
antigen specific CD4 T cell subsets that secreted IFNγ, IL-2 or IL-4 to determine 147 
which of these subsets may correlate with the observed B-cell and/or ADCC 148 
responses. 149 
 150 
 151 
152 
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Materials and Methods.   153 
 154 
As a well characterised model HIV-1 immunogen that has been used in human and 155 
non-human vaccine trials, we used the recombinant HIV-1 gp140 of the subclade B 156 
SF162  (27, 28) from which pathogenic SHIV has been developed (29). To prevent 157 
CD4 receptor engagement a mini CD4 peptide (M64U1-SH) was used to cross-link 158 
the gp140dV2SF140, as described by Van Herrewege and Dereuddre-Bosquet (30, 159 
31). Cross-linking of the mini-peptide mimicking the CD4 receptor binding site to 160 
gp140 was described by Martin et al. (22) which effectively (Fig. 1; (23)) occludes 161 
critical Env CD4bs sites such as residue 375 (32).  162 
 163 
Animals and immunizations  164 
A total of 24 mature captive-bred male rhesus macaques (Macaca mulatta) were 165 
housed at the Biomedical Primate Research Centre (BPRC), The Netherlands. The 166 
rhesus macaques were negative for antibodies to SIV, simian type D retrovirus and 167 
simian T-cell lymphotropic virus at the initiation of the study. The study protocol and 168 
experimental procedures were approved by the institute’s animal ethical care and use 169 
committee and were performed in accordance with Dutch law and International 170 
ethical and scientific standards and guidelines. Behaviour, discomfort, and appetite 171 
were observed daily during the study by specially trained personnel. Body weight and 172 
body temperature were measured before the start of the experiment and each time the 173 
animals were sedated for immunization and/or blood sampling immediately following 174 
sedation of each individual animal.  175 
The study consisted of 24 animals divided into four groups of 6, randomized based on 176 
age and weight. All groups received 0.5 ml of the MF59 adjuvant IM (upper leg) to 177 
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formulate the protein while the last group served as the adjuvant only control. Group 178 
1 animals were immunized with gp140 with its CD4bs-blocked (gp140 CD4bs-x = 179 
100 µg of gp140DV2SF162 with the CD4bs blocked by the mimetic M64U1-SH). Group 180 
2 animals were immunized with the same but unblocked gp140 (100 µg of 181 
gp140DV2SF162), while group 3 received the mimetic M64U1 as a control, while group 182 
4 was the adjuvant only control group (0.5 ml of the adjuvant MF59). All animals 183 
were immunized at weeks 0, 4, 24, 36. To assess the durability of vaccine-induced 184 
responses animals, immune responses were followed up to week 107 (71 weeks post 185 
4th Immunization (Fig. 2). 186 
For immune assays serum, plasma and peripheral blood mononuclear cells (PBMC) 187 
were isolated from blood samples collected from sedated animals (ketamine 188 
hydrochloride anesthesia, 10mg/kg) at regular time intervals aseptically (Vacutainer, 189 
Becton Dickinson). To investigate possible adverse effects, body weight, rectal 190 
temperature, routine haematology and clinical chemistry were performed at regular 191 
intervals.  192 
 193 
Humoral immune responses: Binding antibody titers and neutralization assay 194 
Antibodies to HIV-1SF162 Env (gp140) in serum were measured by ELISA. Plates were 195 
coated overnight with Env in 100mM NaHCO3 and were blocked for 1 hour with 1% 196 
non-fat milk before application of serum, serially diluted in 1% BSA PBS buffer. 197 
After 1 hour 1µg/ml anti-human IgG-HRP conjugate was added for an additional hour 198 
before the addition of ultra-TMB ELISA development reagent. The reaction was 199 
stopped by addition of 0.5M H2SO4. Results were expressed as IgG endpoint dilution 200 
titers. 201 
For the standardized and validated neutralization assays the TZM-bl cell line was used 202 
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(33, 34). It was obtained through the NIH AIDS Research and Reference Reagent 203 
Program, Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu 204 
and Tranzyme Inc. The HeLa cell line was engineered to express CD4 and CCR5 205 
receptors. Following infection with SHIV pseudotyped virus the cells produce 206 
luciferase, the activity of which was detected by chemi-luminescence. Sera were 207 
diluted to give a 1 in 20 dilution and subsequently in a threefold series to a final 208 
dilution of 1 in 43,740. Each dilution was mixed with sufficient pseudovirus to give 209 
500,000 counts per second in a Perkin-Elmer Victor 6016971 luminometer. The 210 
mixture included 15 µg/ml of DEAE and was then incubated for one hour before 211 
10,000 TZM-bl cells were added. The cells were cultured for 48 hours, the 212 
supernatants removed and the cells lysed. The cell lysates were transferred to black / 213 
white plates, britelite reagent added and the luciferase activity quantified. Antibody 214 
titers are expressed as the dilution of serum required to reduce the luciferase activity 215 
in cultures exposed to pseudovirus alone by 50% (35–37). As a positive control for 216 
the detection of CD4i neutralizing antibodies, a modified neutralization assay using 217 
HIV-27312A pseudovirus was used as previously described (38). 218 
 219 
B-cell Elispots 220 
Antigen specific B-cell counts were performed as described by Crotty et al. (39). 221 
PBMC were plated in 48 well plates at 1x106 cells/ml in complete medium (RPMI 222 
1640 with L-Glutamine, P/S, HEPES buffer and 10% Fetal Bovine Serum) 223 
containing: PWM (Pokeweed Mitogen) at the dilution of 1:10,000, SAC 224 
(staphylococcus Aureus Cowan Strain –1) at the dilution of 1:10,000, β-mercapto-225 
ethanol at the dilution of 1:000, 20U/ml IL2; IL4; IL5; IL6 and CpG oligonucleotide 226 
at a concentration of 5 μg/ml. Plates were incubated at 37oC, 5% CO2 for 5 days. To 227 
Improved B-cell responses via CD4bs occluded Env 
 
 11 
enumerate Ag-specific B-cell Antibody Secreting Cells (ASC) or spot forming units 228 
(SFU), 96-well plates were coated with 50 µl/well gp120SF162 Env antigen at 5 μg/ml 229 
final concentration. After 18 hours, plates were washed and blocked with 100 μl/well 230 
complete medium at 37oC for 1-2 hours prior to use.  231 
 On day 6, the cells were washed thoroughly, plated onto the ELISPOT plates 232 
and incubated 37oC 5% CO2 overnight. Plates were washed with phosphate buffered 233 
saline (PBS) followed by PBS containing 0.05% Tween-20 (PBST). Plates were then 234 
incubated overnight in 1 μg/ml Biotinylated-goat-anti-rhesus Ig (Hybridoma Reagent 235 
Laboratory) in PBST with 2% FCS. Plates were again washed and then developed 236 
using 5 μg/ml HRP-conjugated avidin dilution in PBST, incubate for 1-2 hours at 37o 237 
C. Plates were washed again and then developed using 3 amino-9 ethyl-carbazole 238 
(AEC, Sigma) and give spot formation. The reaction was stopped by washing the 239 
plates with tap water. Spots were counted using the AELVIS ELISPOT reader. Data 240 
are presented as number of Antibody Secreting Cells (ASC)/1x106 PBMC. 241 
 242 
ADCC assays.  243 
ADCC assays were performed as previously described by Pollara et al. (40), using 244 
CEM.NKRCCR5 cells coated with recombinant HIV-1 SF162gp120 as target cells, and 245 
PBMC obtained from an HIV-seronegative donor as effector cells. The ADCC-246 
mediating antibody titer was defined as the reciprocal of the highest dilution 247 
indicating a positive GzB response (>8% GzB activity) after background subtraction 248 
as previously described (40).  249 
 250 
T-cell Elispots 251 
Enumeration of antigen specific IFN-g, IL-2 and IL-4 cytokines was measured using 252 
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an ELISpot assay as described by Koopman et al. (41). Separate peptide pools, 253 
consisting of 15mers with an 11 amino acid overlap, which covered the entire gp41 254 
and gp120 of SF162 (NIH, AIDS reagent program) were used to measure antigen-255 
specific immune responses after each immunization, during follow up and after 256 
challenge. Medium alone was used as negative control, whilst PMA (20ng/ml) plus 257 
ionomycin (1μg/ml) stimulation was used as positive control. In brief, 4x106 cells/ml 258 
were stimulated in RPMI-1640 medium supplemented with 10% fetal calf serum 259 
(FCS) in a 24-well tissue culture plate for 24 hours. For the enumeration of antigen 260 
specific cytokine production, non-adherent cells were collected and plated at 2x105 261 
cells/well in triplicates in a 96-well ELISpot plate with the same antigen. Microtiter 262 
plates were pre-coated with mAbs; anti-IFN-g mAb (MD-1, U-Cytech, Utrecth, The 263 
Netherlands), anti-IL-4 mAb (QS-4, U-Cytech) and anti-IL-2 mAb (B-G5, Diaclone 264 
Laboratories, Besançon Cedex, France). Detection of the cytokine secreting cells took 265 
place after 15 hours for IL-4 and 4 hours for IFN-g as well as IL-2. The cells were 266 
lysed and the debris was washed away before adding detector antibodies. IFN-g, IL-2 267 
and IL-4 were detected using biotinylated rabbit-anti-rhesus IL-2, biotinylated rabbit-268 
anti-rhesus IFN-g, or biotinylated mouse-anti-rhesus IL-4 (U-Cytech). Spots were 269 
visualized using streptavidin-HRP and an AEC (3-amino-9-ethylcarbazole) coloring 270 
system.  271 
 272 
CD4 T-cell Proliferation inhibition assay 273 
PBMC were incubated ON at 4 °C in RPMI with 10% FCS containing either 274 
SF162gp140 (CD4bs-open) (1 µg/ml/106 cells), SF162gp140CD4bs-occluded (1 275 
µg/ml/106 cells) or no additions. Cells were subsequently harvested and labelled with 276 
CellTrace (CellTace Violet cell Proliferation Kit, Molecular Probes, Invitrogen, 277 
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Carlsbad, CA, USA, 20 min. incubation at 37 °C, 1 µl Cell Trace/ml/106 cells). Cells 278 
were then incubated for 72 hours on CD3 coated microwell plates (coated with 1 279 
µg/ml CD3 clone SP34 (Becton & Dickinson), 2 hours incubation at 37 °C then 3 280 
times wash with PBS) either without additions, with SF162gp140 (CD4bs-open) (1 281 
µg/ml) or with SF162gp140CD4bs-occluded (1 µg/ml). Cells were then stained with 282 
CD3APC and CD4PE-Cy7 and expression of Cell Trace Label was detected by FACS 283 
analysis. 284 
 285 
Statistical analyses 286 
The statistical significance of differences between responses induced by the different 287 
(CD4bs-occluded or open gp140) immunogens was determined by Dunnett’s Multiple 288 
Comparison Test (one-way analysis of variance (ANOVAR)), Dunn’s Multiple 289 
Comparison Test (non-parametric test) or Bonferroni post tests (two-way ANOVAR). 290 
For IFN-γ and IL-4 the area under the curve (AUC) was calculated for weeks 22-26, 291 
whereas week 22 data were used for IL-2 (week 26 data not available). Correlations 292 
between cytokine AUC, B-cell ELISpot and ADCC were then assessed using 293 
Spearman’s Rho (Non-Parametric test). ELISpot AUC were calculated for the 294 
induction phase (weeks 22-38) and CD4bs-occluded or open gp140 immunized 295 
groups were compared non-parametrically (Mann-Whitney U test).  296 
 297 
298 
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Results. 299 
 300 
Immunisation kinetics of B-cell responses in Rhesus macaques immunized with 301 
HIV-1 Env occluded at the CD4 binding site. 302 
We set out to test our hypothesis that CD4 binding HIV-1 envelope immunogens 303 
could potentially be detrimental to achieving optimal and durable vaccine induced B-304 
cell responses. In addition to the structural evidence of occlusion the CD4bs on the 305 
Env protein (Fig. 1, (23)) we performed an exploratory FACS-based assay to confirm 306 
the inhibitory effect of SF162gp140 on rhesus CD4 T-cell proliferation in the 307 
presence of anti-CD3 in vitro (Fig. 3). This assay confirmed that gp140 inhibition of 308 
CD4 T-cell proliferation was abrogated by using the M48U1 CD4bs-occluded form of 309 
Env protein. The vaccine study was performed in 24 Rhesus macaques divided into 310 
the immunization-active and long-term follow-up or durability phase as indicated in 311 
Fig. 2. Animals were immunized four times over 40 weeks (Fig. 2A) and vaccine 312 
induced antigen specific B-cells in peripheral blood enumerated.  313 
Throughout the immunization phase (Fig. 4A) of the study the gp140CD4bs-x 314 
(CD4bs-occluded) vaccine group developed significantly (p < 0.001) higher numbers 315 
of Ag-specific B-cells than the gp140 (CD4bs-open). Despite the expected individual 316 
variation in the number of circulating Env-specific B-cell ELISpots found, there were 317 
consistent and significant differences between the two Env vaccinated groups. Two 318 
weeks after the second immunization, these numbers were the highest in group 1 319 
(gp140CD4bs-x) ranging between 250 and 1,865 ELISpots/106 PBMCs versus a 320 
lower range between 105 to 975 ELISpots/106 PBMCs for macaques immunized with 321 
gp140 alone. Both groups reached statistical significance with the gp140CD4bs-322 
occluded group being consistently higher by the second immunization and increasing 323 
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further after the third immunization, reaching a peak plateau in the gp140CD4bs-324 
occluded group, with a range from 3,630 to 11,823 ELISpots/106 PBMCs by week 26 325 
(Fig. 4A). Macaques receiving gp140 (CD4bs-open) required a fourth immunization 326 
to reach a plateau, responses which were at a lower range; from 1,550 to 4,365 327 
ELISpots/106 PBMCs by week 38 (Fig. 4A). The CD4bs-occluded group had 328 
significantly (p < 0.001) and consistently higher numbers of circulating Ag-specific 329 
B-cells than the CD4bs-open group throughout the entire immunization schedule. 330 
This demonstrated a significant and positive impact on the kinetics of priming and 331 
development of B-cell responses by simply altering the CD4bs on Env antigen to 332 
prevent CD4 receptor binding by Env vaccine antigen. A minor background response 333 
in the CD4 mimetic minipeptide and adjuvant control groups was detectable at only 334 
one time point (week 20) over the entire study). 335 
 336 
Antibody titers to total Env are primed first and peak earliest in CD4bs-337 
occluded Env immunized animals 338 
During the active immunization phase of the study the early appearance of antibodies 339 
reflected the early appearance of Ag-specific B-cells in circulation in the CD4bs-340 
occluded Env group compared to the CD4bs-open gp140 Ag (Fig. 5A). Total Env 341 
binding antibodies were detectable and higher within 6 weeks, two weeks after the 342 
second immunization in the CD4bs-occluded Env immunized group, already 343 
comparable to mean Env titers observed in the gp140 group after the third 344 
immunization (Fig. 5A). Titers again increased markedly after the third immunization, 345 
peaking at week 24 until a plateau was reached at week 40. Antibody titers in these 346 
immunized macaques were significantly (p > 0.0001 in a two-way ANOVAR) greater 347 
than those induced with gp140 (CD4bs-open) during the active immunization phase 348 
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(A), four weeks after the fourth immunization suggesting a positive impact of 349 
occluding the CD4bs of gp140 on priming and the magnitude of anti-Env titers 350 
reached during the immediate immunization period (Fig. 5A). 351 
 352 
Neutralizing antibodies peak earlier and show activity against HIV-2 in the 353 
presence of soluble CD4. 354 
To accurately assess neutralization of HIV-1 enveloped viruses in Rhesus macaques, 355 
we turned to in vivo Rhesus adapted SHIV viruses using the lentivirus pseudotype 356 
system to avoid differences in non-envelope encoded differences in their genomes. 357 
Importantly, early in the immunization protocol, CD4bs-blocked gp140 immunized 358 
animals induced the first neutralizing antibody response to the relatively homologous 359 
Tier 1 SHIVSF162P4 observed at weeks 22 and 24 (p < 0.001 in one-way ANOVAR) 360 
(Fig. 6). Subsequently, neutralizing antibody titers increased after each immunization 361 
until the third immunization when slower developing neutralizing titers in the gp140 362 
group had eventually caught up with the CD4bs-blocked group. By the third 363 
immunization (week 24) there was a boost in homologous neutralizing titers in the 364 
gp140 group that reached similar levels to the CD4bs-blocked group (Fig. 6). Given 365 
that globally, the Env neutralizing epitopes were otherwise identical in the CD4bs-366 
blocked versus open gp140, this was not unexpected (with exception of fine 367 
specificity differences of CD4i epitopes caused by CD4bs-M48U1 cross-linking (42)). 368 
Due to the slower acquisition of heterologous neutralizing antibodies, later time-point 369 
sera collected at weeks 38 and 42 (2 or 6 weeks post 4th Immunization) were 370 
measured for neutralization against clade B SHIV virus strains. In the pseudotype 371 
system these included Tier 1 SHIV89.6, SHIVW6.1D and Tier 2 SHIVSF162p3, as well as 372 
HIV-2. 373 
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Based on the observation that HIV-1 gp120 bound to CD4 gives a stable 374 
conformation that presents an increased affinity for the chemokine receptors and 375 
CD4i antibodies that also broadly neutralize HIV-2 (43–46). We used sCD4 in our 376 
assays to determine if CD4-inducible neutralizing antibody responses remained intact 377 
in the CD4bs-occluded gp140 group (38). The mean 50% neutralization titers against 378 
Tier 2 SHIVSF162p3 were <20 (in the presence or absence of sCD4; Fig. 7). Against the 379 
SHIV89.6 the mean titers were undetectable (without sCD4) and 1:125 (with sCD4) 380 
while against the Tier 1 SHIVW6.1D the mean titers were 1:355 (without sCD4) and 381 
even higher (with sCD4) in the gp140 immunized group. The mean titers in the 382 
CD4bs-blocked gp140 immunized group were <20 (both against the Tier 2 SF162p3 383 
and 89.6 pseudo viruses), 1:259 against the Tier 1 W6.1D virus all without sCD4, 384 
while the mean titers in presence of sCD4 were <20, 1:135 and higher than 1:540 385 
respectively. Of note, this gp140 was chosen for this proof-of-concept CD4bs-386 
occlusion study because the protein was well characterised and used in many previous 387 
studies, not because of the broad-neutralising Ab epitopes it presented. It was also 388 
selected because of its neutralisation inducing potential for CD4i, one of the control 389 
features for the M48U1 occlusion. Importantly, we observed neutralizing responses 390 
against HIV-2 (Y720S) in the presence of sCD4 in the CD4-bound gp140 group, 391 
confirming that the CD4i epitopes were exposed and functional and induced by this 392 
immunogen (Fig. 7), and independently confirmed in Shen et al (42). 393 
 394 
Superior Antibody Dependent Cellular Cytotoxicity (ADCC) responses elicited 395 
by immunization with CD4bs-occluded Env immunogen 396 
“Non-neutralizing” antibodies are becoming recognized as important vaccine induced 397 
effector responses in protective HIV-1 immunity. Antibody dependent cellular 398 
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cytotoxicity (ADCC) responses have been correlated with slower disease progression 399 
(47–49) as well as vaccine efficacy  (50–52). A high proportion of ADCC responses 400 
in patient sera are directed towards CD4i epitopes (53), those same epitopes we have 401 
preserved by stabilizing with our CD4bs-linked CD4 mimetic complex as we 402 
previously validated (22, 54). To determine if ADCC activity was induced by Env 403 
immunization with the CD4bs-occluded or open gp140, sera from immunized animals 404 
were assayed at weeks 0, 26 and after long-term follow-up. ADCC activity was 405 
measured as the serum titer for mediating Granzyme B release by PBMC upon 406 
incubation with target cells coated with SF162 gp120 protein. Group 1 immunized 407 
with the gp140 CD4bs-occluded had statistically superior ADCC responses compared 408 
to group 2 immunized with gp140 with the CD4bs open with a FDR_p value of 0.014 409 
(Wilcoxon rank sum exact test p value controlled for false discovery rate (FDR) with 410 
the Benjamini-Hochberg method) at week 26 (Fig. 8).  411 
 412 
Circulating antigen specific interleukin-4 (IL-4) CD4 T-cell responses increase 413 
early during immunization with CD4bs-occluded Env immunogen 414 
Immunization with both HIV-1 Env immunogens induced T-cell ELISpots specific 415 
for peptides of the external HIV-1 envelope glycoprotein (gp120) that were detectable 416 
during the active phase of immunization (Fig. 9A) but which tapered off during the 417 
long-term follow-up period (Fig. 9D). These increases were observed with 418 
lymphocytes producing IL-4, IL-2 or IFN-g and reached statistical significance 419 
relative to the 2 groups of control macaques (mimetic and adjuvant controls). These 420 
data were analysed in a two-way analysis of variance with all time-points included 421 
where data from all twenty-four macaques were available.  422 
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Importantly the earliest and most robust T-helper responses were observed in 423 
macaques immunized with gp140-CD4bs-occluded which induced the highest number 424 
of IL-4 producing ELISpots found at week 26 (p=0.025) (Fig. 9A) for both gp120 and 425 
gp41 sets of peptides (HIV-1 gp120, p < 0.0001(Fig 9A); HIV-1 gp41, p < 0.0001 426 
(gp41 data not shown). The highest number of IL-2 producing ELISpots recognizing 427 
HIV-1 gp120 peptides was seen after three immunizations at week 34 (p < 0.01). The 428 
IFN-g ELISpots peaked at week 38 (gp120, p < 0.0001; Fig. 9A). All six gp140 429 
immunized macaques induced more than 50 IFN-g producing lymphocytes per million 430 
PBMCs at week 38 while five of the macaques immunized with the CD4bs-occluded 431 
Ag induced this same level of ELISpot activity while four also had more than 50 IL-2 432 
and IL-4 producing lymphocytes. While macaques immunized with gp140 only did 433 
not have increased numbers of HIV-1 gp41 specific, g-interferon producing ELISpots 434 
overall, numbers were significantly increased, relative to control macaques, at weeks 435 
38. 436 
Immunizations at weeks 24 and 36 each produced an increase in the number of T-cell 437 
ELISpots recognizing either HIV-1 gp120 or gp41 peptides in both the gp140 alone 438 
and gp140 CD4bs-occluded groups (Fig. 9A; data not shown). This pattern was 439 
observed following each immunization with the exception of IL-2 ELISpots at week 440 
36. Also with the exception of IL-2 at week 38, ELISpot numbers at weeks 26, and 38 441 
were statistically significantly higher than controls at these time-points. Peak levels 442 
were found after four immunizations (week 38; g-IFN, p < 0.0001 and IL-4, p < 443 
0.0001). The gp140-CD4bs-occluded and gp140 groups induced statistically 444 
significant numbers of IL-4, but not IL-2 producing ELISpots recognizing peptides 445 
from the HIV-1 transmembrane envelope glycoprotein (gp41) (data not shown). The 446 
number of ELISpots responding to gp41 peptides were lower and delayed with their 447 
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highest levels seen after five immunizations for all three cytokines (data not shown). 448 
In summary, during the active immunisation phase (panel A Fig. 9), CD4bs-occluded 449 
gp140 immunisation induced earlier and more robust IL-4 (week 26 p=0.025), as well 450 
as trend for earlier IL-2 responses (p=0.065), suggesting a more vigorous and early 451 
recruitment of CD4+ T-helper cells during the inductive phase of the B-cell response 452 
(Fig. 4A). 453 
 454 
Durability of B-cell responses 455 
A key concern of HIV-1 vaccine development has been the very poor durability of 456 
HIV-1 vaccine induced responses, especially B-cell responses (52, 55–57). To address 457 
this, after an active immunization phase with 4 immunizations given over 40 weeks, 458 
we embarked on a long-term follow-up phase where animals were rested without 459 
sedation and protocol bleeds for approximately 70 weeks (1.5 years) to determine the 460 
durability of B and T-cell immune responses.  461 
Importantly, while the plasma antibody titres gradually contracted after boosting, the 462 
superior numbers of Ag-specific B-cells in circulation were sustained in the CD4bs-463 
occluded group throughout the long-term follow-up with a slight decline over the long 464 
70 week period (Fig. 4 phase D). Despite these impressive and durable levels of Ag-465 
specific B-cells during the active (Fig. 4 phase A), and the early higher titers and peak 466 
of total anti-Env antibodies in the CD4bs-occluded group, during the 70 weeks of 467 
observation in the durability phase (Fig. 5 phase D), total Env titers began to wane. 468 
The higher titer of total Env antibodies slowly decayed and after the 1 year endpoint 469 
(week 107) to levels similar to the gp140 “open” immunized animals (Fig. 5 phase D). 470 
This suggested that the global antibody response produced by the plasma cell pool 471 
that had accumulated during immunisation, had reached a maximum equilibrium 472 
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despite the impressive and sustained kinetics of the Ag-specific memory B-cells in 473 
circulation. 474 
Control macaques immunized or with the CD4-mimetic or adjuvant alone had no 475 
specific antibody to gp140. Macaques immunized with gp140 CD4bs “open” 476 
produced low levels of antibodies that transiently cross-reacted with the CD4-mimetic 477 
peptide at week 26 (data not shown). Antibodies to the mimetic peptide were not 478 
detectable in other macaques.   479 
Remarkably the long-term durability of Env-specific memory B-cells in circulation 480 
correlated with more robust ADCC responses (p<0.001, spearman 0.85) which were 481 
also found to be durable during the extended long-term follow-up of more than 70 482 
weeks (Fig. 8).  483 
 484 
 485 
Discussion. 486 
 487 
This study set out to determine if rationale HIV-1 Env-antigen design could improve 488 
B-cell responses in primates. High affinity CD4 binding associated with HIV-1 Env 489 
residue 375 substitutions have been associated with increased virulence in macaques 490 
(32). We reasoned that if we could prevent CD4 binding by envelope antigens, yet 491 
preserve key CD4-inducible (CD4i) epitopes which were important for virus 492 
neutralization and rich in ADCC epitopes, that we could provide the basis for an 493 
improved HIV-Env antigen scaffold which could be suitably modified for future 494 
presentation of key broad neutralising epitopes, and ultimately deletion of dominant 495 
non-conserved antigen decoys. Our design criteria were two fold; CD4 binding site 496 
occlusion and preservation of CD4i Nab epitopes, both which we have demonstrated 497 
in previous structural and small animal studies (22, 25, 26). Our immunological 498 
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criteria required an in vivo primate CD4 T-cell system compatible with HIV-1 Env 499 
binding to study the in vivo inductive events in the presence of functional CD4 gp140 500 
interaction in vivo. Our immunological criteria included; improved B-cell responses 501 
with respect to magnitude and durability, preservation of CD4i epitopes and induction 502 
of ADCC, and evidence for improvement of one of more of the antigen specific T-cell 503 
subsets (IFN-γ, IL-2 & IL-4).  504 
When HIV-1 gp120 binds to CD4 it stabilize the virus envelope in a conformation 505 
that presents an increased affinity for the chemokine receptors and CD4i antibodies 506 
(43–46). The bound envelope glycoproteins offer therefore different targets both to 507 
induce and bind antibodies. Recent studies evaluating the evolution and specificities 508 
of broadly-neutralizing antibodies during HIV-1 infection (38, 58, 59) have provided 509 
important insights regarding the significance of CD4i antibodies and their potential 510 
role in vaccine against HIV-1. So far, recombinant monomeric gp120 or 511 
oligomeric/trimeric gp140 glycoproteins have failed to elicit broad and potent 512 
neutralizing antibodies in experimental animal models. Past studies based on gp120-513 
CD4 (or CD4 mimic) complexes or constrained ‘core’ gp120 antigens have been 514 
evaluated as vaccine candidates, aiming at inducing CD4i antibodies (26, 60–63) 515 
Fouts et al. demonstrated that gp120 cross-linked to CD4 D1D2 domains raised 516 
antibodies that neutralized primary viruses regardless of co-receptor usage and genetic 517 
subtype in nonhuman primates (61). These findings were extended in a challenge 518 
study by DeVico et al. (60) where macaques immunized with a single chain complex 519 
containing gp120BaL-rhesus macaque CD4 D1D2 showed improved CD4i antibody 520 
response that correlated with the control of infection when challenged with 521 
SHIVSF162P3. Although this correlation did not prove that efficacy was mediated by 522 
neutralizing CD4i antibodies, it demonstrated that the presence of CD4i Abs was 523 
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dependent on the CD4- bound conformation of HIV-1 envelope in vivo. These studies 524 
demonstrated the potential importance of strategies directed to raising antibodies 525 
against the CD4i site. Recently we used a practical approach of eliciting CD4i 526 
epitope-directed virus neutralizing antibodies using a stably cross-linked complex of 527 
recombinant oligomeric gp140 and miniCD4 (M64U1-SH) (22, 31) to target the 528 
conserved co-receptor binding site of the HIV-1 Env. In those studies, two CD4 529 
mimetic mini proteins (miniCD4) were cross-linked to various forms of HIV-1 Env 530 
(M64U1-SH). Based on results from those studies, the M64U1-SH miniCD4 was 531 
selected for generating the cross-linked gp140-miniCD4 complex.  532 
Two important under appreciated issues were addressed in this study. First was the 533 
observation that binding or cross-linking of the CD4 molecule of T-helper cells causes 534 
functional impairment (11, 12, 64–66) and within germinal centres. The hypothesis 535 
was that CD4 binding by antigen would impair critical interactions between Ag 536 
specific CD4 Tfh cells and MHC II B-cells which are fundamentally important in 537 
generating memory B-cell responses and functionally important antibody effector 538 
responses such as neutralising (n)Ab and ADCC. The second was that CD4i epitope 539 
regions are also rich in ADCC epitopes (53), thus stabilizing their presentation would 540 
promote such ADCC in naive vaccinated individuals. Importantly, in this study, by 541 
simple cross-linking of the small CD4 receptor mimetic to the CD4 binding site of 542 
gp140 we have been able to demonstrate; 1) preservation of CD4i nAb, 2) improved 543 
and long-term durable B-cell responses, 3) early induction of anti-HIV-1 binding and 544 
nAbs, and 4) ADCC. The early and robust CD4 T-helper responses characterized by 545 
IL-4 secretion correlated with the early induction of B-cell and antibody responses, 546 
suggesting that preventing CD4 binding of the Env antigen in B-cell inductive sites 547 
was an underlying and important feature of this antigen modification. These findings 548 
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beg mechanistic follow-up studies to prove this hypothesis and to understand the in 549 
vivo half-life and kinetics of gp140 in the CD4bs-occluded, M48U1-complexed 550 
versus the unbound forms, in lymph nodes draining vaccine injection sites.  Most 551 
notability the induced B-cell responses were durable for more than 1.5 years post-552 
immunization, representing a major advance in a key area of HIV vaccine 553 
development. Future modifications to further improve Env antigen structures with 554 
additional modifications to better present and recruit key bnAb and ADCC epitope 555 
rich regions are likely to ultimately contribute to more highly effective HIV-1 556 
vaccines. 557 
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Legends.        882 
 883 
Figure 1.  884 
Zoomed-in view of M48U1 binding site showing close contact (pink dotted line) 885 
between M48U1 cyclohexylmethoxy group Phe23 and gp120YU2 Ser375. Gp120 is 886 
shown as a transparent surface. M48U1 is shown in cyan cartoon representation with 887 
its 23 residue represented as sticks. Illustration was prepared with the Pymol 1.8.2.1 888 
Open-Source using 4JZZ PDB ID. The interaction between cyclohexylmethoxy (U1) 889 
in M48U1 with both main chain and side chain O atoms of Ser375 gp120 (23).  890 
 891 
Figure 2.  892 
Immunization schedule and long-term (17.5 months/70 week) follow-up depicting the 893 
immunization phase (box A), and durability phase (box D). 894 
 895 
Figure 3.  896 
SF162gp140 mediated inhibition of CD3/TCR induced CD4 T-cell proliferation is 897 
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prevented by CD4bs occlusion. In each graph bars are used to indicate the number of 898 
undivided cells (right hand bar) and the number of cells for each cell division, within 899 
the CD3CD4 population. Note the difference in the fraction of undivided cells, which 900 
is increased after addition of SF162gp140 (CD4bs-open), but not by 901 
SF162gp140CD4bs-occluded.  902 
 903 
Figure 4: Env specific B-cells in peripheral blood (ASC/1x106 PBMC) per group 904 
during the immunization phase (box A) (at 0, 4, 24, 36 weeks) and after 70 weeks of 905 
long-term follow-up (box D). The frequency of Env specific memory B cells were 906 
determined by B cell ELISpots in animals immunized with gp140 CD4bs-occluded 907 
group 1 (black diamonds), gp140 CDbs open group 2 (=black squares). Control 908 
groups; group 3 (mini CD4 mimetic only lower value black triangle) and group 4 909 
(MF59 only: open squares). Immunizations were given at weeks 0, 4, 24, and 36 (box 910 
A). The values (numbers of Antibody Secreting Cells (ASC) per 106 PBMCs) are 911 
means from 6 animals per group ± standard deviations (error bars).  912 
* = points where p > 0.001 (two-way ANOVAR). 913 
 914 
Figure 5: Kinetics of anti-Env titers per group during the immunization phase (at 0, 4, 915 
24, 36 weeks) (box A) and after 70 weeks of long-term follow-up (box D). HIV-1SF162 916 
gp140 specific binding antibody responses induced after immunization with gp140 917 
CD4bs-occluded (group 1: black diamonds), gp140 CDbs open (group 2 =black 918 
squares), group 3 immunization mini CD4 mimetic (black triangles), and control 919 
group 4 immunized with MF59 only (group 4: open squares). The values (binding 920 
end-point titers) are means of 6 animals per group ± standard deviations (error bars). 921 
*= p > 0.0001 (two-way ANOVAR). 922 
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 923 
Figure 6: Early induction of neutralization responses in gp140 CD4bs-occluded 924 
(black diamonds) and gp140 CD4bs-open immunized animals (black squares).  925 
Neutralization of relatively “homologous” SHIVSF162p4 by sera from immunized 926 
animals. Antibody titers are expressed as the dilution of serum required to reduce the 927 
luciferase activity in cultures exposed to SHIVSF162p4 pseudovirus alone by 50%. The 928 
values are means from 6 animals per group ± standard deviations (error bars). 929 
Elevated early responses detected 18 and 20 weeks after the second immunization 930 
(administered at 4 weeks); 22 and 24 weeks after first immunization. Subsequently 931 
homologous neutralization titers became similar in both Env immunized groups.  932 
* = p < 0.001 (one-way ANOVAR). 933 
 934 
Figure 7. Heterologous neutralizing activity in the presence or absence of soluble 935 
CD4 during the immunization phase. Heterologous neutralization of a panel of clade 936 
B SHIV pseudoviruses with sera taken at 2 or 6 weeks post 4th vaccination. 937 
Comparison of neutralization activity of sera from animals immunized with gp140-938 
CD4bs-x (occluded group: circles) in the absence (-sCD4) or presence of sCD4 939 
(+sCD4) versus gp140 CD4bs open (squares). To confirm that the CD4i epitopes in 940 
the gp140-CD4bs-x immunized group (1) were exposed and functional, sera was 941 
tested against the HIV-27312A pseudovirus. IC50 neutralization titers are indicated 942 
against different viral isolates. The symbols represent values from individual animals 943 
while the horizontal bars are means of 6 animals per group ± standard deviations 944 
(error bars). 945 
 946 
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Figure 8. ADCC activity in CD4bs-x (occluded; black diamonds) Env immunized 947 
animals versus CD4bs-open (black squares) Env immunized animals. Data shown are 948 
two weeks after third immunization and after long-term follow up post 4th 949 
immunization (*p value of 0.014; LOD: limit of detection). 950 
 951 
Figure 9. Env specific cytokine-secreting T-cell ELISpot responses following 952 
immunizations at 0, 4, 24 and 36 weeks (immunization phase left panel A) and long-953 
term 70 weeks follow-up (durability phase, panel D). Shown are IL-4 (upper row), IL-954 
2 (middle row) and IFN-g (lower row) secreting SFU over time. ELISpots from 955 
individual animals immunized with gp140-CD4bs-x (occluded group) first column, 956 
gp140-CD4bs open (2nd column), mini CD4 mimetic only (3rd column) and adjuvant 957 
only (4th column). Background responses (mean numbers of spots plus 2x the standard 958 
deviations of triplicate assays with medium alone) were subtracted. Responses after 959 
stimulation with overlapping SF162 gp120 20mer peptides are presented as the 960 
number of spot forming cells (SFC) per 106 PBMCs.  N.S.: no significance. 961 
 962 
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